Grants and Contributions:
Title:
A feasibility study to determine the potential to develop a low dose solid dose formulation of psilocybin.
Agreement Number:
1005949
Agreement Value:
$75,000.00
Agreement Date:
Apr 1, 2023 - Sep 30, 2024
Description:
The project aims to develop a solid dose formulation of Diamond Therapeutic's first drug candidate for use in advanced clinical studies. Requirments for formulation development for a later stage clinical program include certain stability and other characteristics necessary for a regulatory approval and ultimately a commercial product.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5R 1T9
Reference Number:
172-2023-2024-Q2-1005949
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
739218683
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 199 days.
Amendment Date
Mar 26, 2024
Recipient's Operating Name:
Diamond
Recipient's Legal Name:
Diamond Therapeutics Inc.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: